| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tipifarnib | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | Sorafenib | FIMM | pan-cancer | AAC | 0.12 | 0.6 |
| mRNA | BRD-K66453893 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | BRD-A02303741:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.024 | 0.6 |
| mRNA | avrainvillamide | CTRPv2 | pan-cancer | AAC | -0.026 | 0.6 |
| mRNA | prima-1 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.023 | 0.6 |
| mRNA | WAY-362450 | CTRPv2 | pan-cancer | AAC | -0.023 | 0.6 |
| mRNA | BRD-K49290616 | CTRPv2 | pan-cancer | AAC | -0.047 | 0.6 |
| mRNA | WZ4002 | CTRPv2 | pan-cancer | AAC | 0.027 | 0.6 |